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Effectiveness Analysis Registry between 2000 and 2007. Data were extracted on
publication year, target population, intervention, patient sample, disease, preven-
tion stage, and incremental cost-utility ratio of each economic evaluation. Preven-
tive interventions were defined as measures preventing disease onset. Curative
interventions related to measures identifying patients with risk factors or preclin-
ical disease or interventions limiting disability after harm has occurred. Results
were expressed in terms of costs (valued in 2008 Euro) per quality-adjusted life
year. The association between incremental cost-utility ratios and prevention stage
was examined by means of the Mann-Whitney U-test. RESULTS: The analysis
included 231 studies that reported information about 608 incremental cost-effec-
tiveness ratios. Preventive interventions included interventions that were more
effective and less expensive than comparators (41% of incremental cost-effective-
ness ratios), and interventions that improved outcomes and increased costs (59%).
Both preventive and curative interventions covered the full range of cost-effective-
ness results. However, preventive interventions had a significantly lower median
ratio of 6,255 €per quality-adjusted life year and were thus more cost-effective than
curative interventions (12,917 € per quality-adjusted life year) (p  0.002).
CONCLUSIONS:Although the cost-effectiveness of preventive interventions varies
substantially, preventive interventions tended to be more cost-effective than cu-
rative interventions.
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TENDERING OF BIOSIMILARS IN THE UK – DOES LAUNCH PRICE ACTUALLY
MATTER?
Viejo Viejo I
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OBJECTIVES: In the light of the austerity drives and cost containment practices,
payers increasingly resort to procurement procedures in order to award contracts
for the supply of both conventional drugs and biosimilars. The tough reality of
health care economics in conjunction with the commitment of large generic man-
ufacturers, who continue to invest despite the challenges, may mean that tender-
ing of biosimilars may actually be a tool to increase biosimilars’ market share by
demonstrating price competitiveness.This study aims to evaluate how initial list
price, together with other considerations about efficacy and safety, could influence
the hospital formulary inclusion of new biosimilar drugs in the UK. METHODS: A
data framework was developed from secondary research of existing biosimilar list
prices, product profiles, clinical data submitted and current landscape. The frame-
work was validated through phone-based interviews across different regions in the
UK (n10) targeting Hospital procurement Pharmacists in 2011. RESULTS:Majority
of respondents indicated price to be the primary criteria for formulary inclusion
although some pharmacists highlighted efficacy and safety parameters as influ-
encing factorsCONCLUSIONS:The development of clinical commissioning consor-
tia and the expansion of the biosimilar market as major biologicals come off patent
mean that more decisions about biosimilar purchasing could be made jointly with
primary care. Tendering as a mode of procurement for biosimilars, removes the
prescriber’s influence which is the acceptance-limiting step for biosimilars cur-
rently due to the concerns on efficacy and safety. From a hospital procurement
pharmacists’ point of view, it is unclear whether a price discount strategy will
favour the introduction of new biosimilars in the UK hospitals as other factors
might have a more important role in the final purchasing decision.
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UTILIZATION OF PHYSIOTHERAPY SERVICES IN HUNGARY
Molics B1, Éliás Z1, Ágoston I1, Vas G1, Endrei D1, Kriszbacher I1, Sebestyén A2, Kránicz J1,
Schmidt B3, Boncz I1
1University of Pécs, Pécs, Hungary, 2South-Trasdanubian Regional Health Insurance Fund
Administration, Pécs, Hungary, 3University of Pécs, Zalaegerszeg, Hungary
OBJECTIVES: Physiotherapy services are reimbursed on a fee for service method in
the ambulatory care in Hungary. The aim of this study is to analyze the utilization
of physiotherapy services in Hungary. METHODS: Data were derived from the fi-
nancial database of the National Health Insurance Fund Administration, the only
health care financing agency in Hungary. We analyzed the year 2008. Medical pro-
cedures which can be performed by physiotherapists were included into the study.
Medical procedures are listed according to the Hungarian version of the Interna-
tional Classification of Procedures in Medicine of WHO. RESULTS: Altogether 151
medical procedures were used by physiotherapists. The following top-11 medical
procedure were responsible for more than half (52.5 %) of total activities: ultra-
sound therapy (8.2 %), iontophorezis (6.5 %), muscle strengthening exercise (4.8 %),
individual training (4.4 %), training for circulation improvement (4.1 %), hand mas-
sage (4.0 %), passive movement of multiple limb (4.0 %), middle frequency treat-
ment (3.8 %), mobilization of joints (3.3 %), exercises against resistance (3.2 %),
education of using medical devices (3.1 %), extension of contracture (3.1 %). Total
annual health insurance reimbursement of physiotherapy services was 7.34 billion
Hungarian Forint (42.7 million USD; 29.2 million EUR). CONCLUSIONS: Physiother-
apy care proved to be a highly concentrated health service where 11 medical pro-
cedures out of 151 are responsible of more than half of activity and health insur-
ance reimbursement.
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OBJECTIVES: ISPOR’s mission is to increase the efficiency, effectiveness, and fair-
ness with which the available health care resources are used to improve health
together with a strong vision be recognized globally as the authority for outcomes
research and its use in health care decisions towards improved health. Despite
modest increases, the membership and conference attendance of health care de-
cision makers still remains low, relative to those involved in academia, industry
and consultancy. Assessing if some of those responsible for utilising HEOR data in
care provision and care practice are aware of ISPOR and its full resources and the
drivers and barriers for involvement could provide an opportunity for increased
membership and active involvement. METHODS: To elucidate the level of aware-
ness of ISPOR, its publications and other resources, interviews were undertaken
with stakeholders within 12 NHS Cancer Networks in the UK. A data framework
was developed to support a series of structured telephone interviews according to
the British Healthcare Business Intelligence (BHBIA) Legal and Ethical Guidelines
for Healthcare Market Research. RESULTS: Spontaneous awareness of ISPOR is
relatively limited within the NHS Cancer Network stakeholders, with even less
awareness to Value in Health. Notable areas of interest were Oncology, Patient Ad-
herence and Persistence and Patient Reported Outcomes Measures. The main bar-
riers to membership of ISPOR was its initial awareness and more effective involve-
ment would be limited due to existing NHS commitments, financial resources and
levels of individual interest /relevance to existing NHS role. Organisational involve-
ment with NHS stakeholder networks would support increased levels of
engagement. CONCLUSIONS: To enhance the awareness of ISPOR, its resources,
conferences and educational support, ISPOR should consider a more targeted
awareness campaign with key NHS clinical networks such as NHS Cancer Net-
works, British Oncology Pharmacy Association and evolving Clinical Commission-
ing Groups.
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OBJECTIVES: Therapeutic monoclonal antibodies (mAbs) are capturing an increas-
ingly larger proportion of the pharmaceutical market. Their specificity for biologi-
cal targets allows them to effectively treat a variety of indications. Yet, despite their
successes, the various stakeholders’ viewpoints in European Union (EU) countries
are often at odds. We explore mAbs as a drug class, specifically, how they are
approved for use by the European Medicines Agency (EMA) and other regulating
bodies and how stakeholders’ opinions diverge from regulatory decisions.
METHODS:The following were summarized for mAbs approved for use in EU coun-
tries from 2000-2011: regulatory approval decisions; comparing and contrasting
payer coverage decisions in selected EU countries; and position statements from
patients, advocacy groups, and medical organizations. Discrepancies between ini-
tial or post-approval regulatory decisions and the statements of the other stake-
holders were highlighted. RESULTS: Nineteen mAbs have been approved by the
EMA during the past 10 years. The summary data show how stakeholders use
clinical data to reinforce their agenda. For instance, bevacizumab has been under-
going battles in both the US and the EU: regulators want to remove specific labeled
indications based on safety and effectiveness data and NICE has advised against
coverage for treating metastatic colorectal cancer, citing inadequate benefits for
the costs, while patients fight for continued access to the therapy to extend their
life at all costs. CONCLUSIONS: After product approval, physicians have tradition-
ally been the key treatment decision makers; however, the influence of other stake-
holders are increasingly affecting the availability and use of drugs. The discordance
between decisions made by regulators and payers has forced drug manufacturers
to not only show that it is safe and efficacious to regulators, but to demonstrate a
product’s value to patients and payers. Incorporating the viewpoints of payers as
well as patients in the drug development process will narrow the gap between
stakeholders.
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OBJECTIVES: Recent increase in competition among hospitals, and managed care,
and the impact of Medicare Prospective Payment System; properly measured hos-
pital performance has become important to evaluate the impact of policies on the
hospital industry. This study assessed the influence of hospital governance on
hospital’s economic performance and efficiency, and it also attempted to system-
atically address the issue of ‘whether participation by insider and outsider busi-
ness community stakeholders on the hospital governing board is related to hospi-
tal’s economic performance’. METHODS: The study was focused on 144
community hospitals in Tennessee; those provided general and acute care services
from 2000 to 2006. An input-oriented and output-oriented Data Envelopment Anal-
ysis (DEA) using multiple input and output variables, which is non-parametric,
flexible, and a mathematical programming approach for the performance assess-
ment, was used to measure the efficiency by estimating the optimum level of
output, conditional upon the mix of inputs. RESULTS: It was found that urban
community hospitals were relatively more efficient than rural community hospi-
tals, and smaller community hospitals were relatively more efficient than their
larger and medium-sized counterparts. Interestingly, the results revealed that
small-sized urban hospitals were relatively more efficient than any other commu-
nity hospital type. From a management and policy perspective type, the study
indicates that both rural and large community hospitals may use urban or small
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community hospitals as models in areas such as following: to improve efficiency by
downsizing the scale of the hospitals, to adopt new marketing strategies, and to
change the cost structure of facility operations. CONCLUSIONS: Results of this
work can be useful for guidance to hospital CEOs and administrators, creditors and
bondholders, health care consultants, public finance and public accounting re-
searchers, public policy analysts, and the government; to gain insights of this issue
of hospital’s economic performance along the above mentioned variables.
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OBJECTIVES: The aim of the study is to show the change in important parameters
of intensive care units in Hungary from the year 2000 to 2010. METHODS: Data of
the analysis was taken from the financial database of the Hungarian National
Health Insurance Fund Administration, the only health care agency in Hungary.
We analyzed the number of hospital beds at intensive care units, the number of
intensive care units, their average bed numbers, market share. RESULTS: The Hun-
garian health care system has had 150-167 intensive care units all over the country.
The teaching and some county hospitals had more then one ICU. That meant
1183-1430 beds during the 10 years. We found the highest number of intensive care
beds in 2006 (1430) which was significantly decreased in 2007-2008 below 1300
beds. The median range of beds at a typical ICU was between 5-9. The market share
of intensive care hospital beds form the total number of acute care hospital beds
increased from 1.8 % in 2000 to 2.9 % in 2011. The proportion of day provided with
ventilation also significantly increased from 29 % in 2000 to 68 % in 2010.
CONCLUSIONS: In Hungary the number of the ICUs and the number of the ICUs’
bed did not change significantly in the last 10 years. During this period, the rate of
the ventilation increased. The Hungarian intensive care units successfully man-
aged to adapt to the changing hospital environment.
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OBJECTIVES: Our objective was to analyze the French HTA decision making pro-
cess of the Transparency Commission (TC) and try to identify unwritten decision
rules which influence a drug’s SMR and ASMR. METHODS: We analyzed the TC
database for the years 2005 to 2010, looking at key points of the TC’s opinions listed
within such as: SMR, ASMR, target population, public health impact, presence of
alternatives, orphan drug status, prescription restriction etc. Using a bivariate
analysis we compared drugs granted: insufficient SMR versus other SMR; ASMR V
versus ASMR IV; ASMR IV versus ASMR I, II and III. RESULTS: We found that drugs
granted an ASMR V more often had alternatives than drugs with an ASMR IV
(89.74% vs. 69.82%, p0.005), while prescription of drugs with an ASMR IV was more
often restricted than for drugs with an ASMR V (p0.01 for hospital-only prescrip-
tion and p0.005 for specialist prescription). The median target population for
drugs with an ASMR IV was also smaller than for an ASMR V (15,000 vs. 97,250). On
the other hand drugs with an ASMR IV more often had no public health impact than
those with an ASMR I-III (55.70% vs. 22.13%, p0.005). Drugs with a high ASMR had
smaller median target population (3,400 vs. 15,000) although there was no differ-
ence in orphan drug status between the two groups (9.47% for ASMR IV vs. 14.07%
for ASMR I-III, p0.20). More drugs with ASMR I-III were paediatric medicines
(30.04% vs. 14.79%, p0.005). CONCLUSIONS: Further analyses are in progress us-
ing additional qualitative criteria extracted from the TC’s opinions and using a
multivariate analysis. Such information would be critical for the development of
TC application dossier.
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OBJECTIVES: To understand how different evidence bases may contribute to
health technology assessment (HTA) across jurisdictions, we reviewed the evi-
dence considered by three HTA agencies supporting reimbursement recommen-
dations for nine drugs. METHODS: We selected nine drugs for which the Canadian
Common Drug Review (CDR), the Australian Pharmaceutical Benefits Advisory
Committee (PBAC), and the National Institute for Health and Clinical Excellence
(NICE) had each provided recent reimbursement recommendations. We reviewed
the clinical and economic evidence considered for each decision and evaluated
whether different evidence bases could have contributed to different HTA
decisions. RESULTS: The three HTA agencies agreed (recommended to reimburse)
for four drugs and reached different recommendations for five drugs. In both cat-
egories, somewhat different evidence bases were used by each agency. For a given
drug, different comparators were sometimes considered by different agencies.
Even when comparators were common across agencies, there was variability re-
garding which clinical trials were considered. All agencies considered data from
direct, randomized trials, but PBAC and NICE accepted indirect comparisons,
whereas CDR did not. Regarding economic outcomes, all NICE decisions made use
of cost-effectiveness (mostly cost-utility) analyses, but cost-minimization ap-
proaches were considered by CDR and PBAC for several drugs. Overall, NICE pro-
vided the most transparent reporting on decision making, and CDR was generally
the least transparent of the three. CONCLUSIONS: HTA drug decisions across the
three countries lack good agreement, and considerable variability exists in the
clinical and economic bases considered by CDR, PBAC, and NICE. The reluctance of
CDR to accept indirect clinical comparisons, and the propensity of NICE to heed
expert advice when analyses were inconclusive may contribute to dissimilar deci-
sions being reached for some drugs. Greater transparency and harmonization of
HTA methods have the potential to improve efficiency in health care decision-
making, and further research analyzing additional HTA drug decisions is war-
ranted.
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OBJECTIVES: To review the existing literature on; i) the definition of the threshold
ii) debate about its use, theory and value and, iii) robust theoretical methods for its
calculation. METHODS: The traditional approach for literature searching makes
use of key terms and Medical Subject Headings (MeSH) that most accurately cap-
ture the range of literature relevant to the piece of work while attempting to min-
imize irrelevant studies. This process requires a degree of expertise (and luck) as to
the terms used, with the potential of missing related but differently specified areas
of the literature and anything not captured in search engines. The alternative
approach is “pearl growing”. This approach uses a pool of relevant papers (“initial
pearls”) to grow the literature both through references and citations until all rele-
vant papers have been discovered. This approach therefore relies on the expertise
of the authors of the published literature rather than the searcher’s knowledge of
applicable terms. RESULTS: The traditional method of searching yielded 34 papers,
only 17 of which were deemed relevant. In comparison pearl growing resulted in
the identification of 76 relevant papers, including all of the 17 papers identified
under the traditional strategy. The focus of many of these papers was to debate the
use of a threshold, the theory underlying it or its value. A small number focused on
methods for estimating its value, with a large majority using the social
willingness-to-pay. CONCLUSIONS: The “pearl growing” approach offers a range of
benefits over traditional methods, including the identification of papers and dis-
tinct sections of the literature not discovered otherwise, although it is limited by
the existing software. The cost-effectiveness threshold has been heavily debated,
but there exists very little literature that attempts to provide a meaningful estimate
of its value or even provide a theoretical framework for its calculation.
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OBJECTIVES: Since 2007, HTA environment has been introduced to evaluate new
drug’s pricing & reimbursement in Korea, and PE submission became one of man-
datory requirements in HIRA (Health Insurance Review Agency). The objective of
this study is to understand the overall process and result under the current envi-
ronment, and to identify factors in the process which might cause a patient access
issue. METHODS: We reviewed DREC (Drug Reimbursement Evaluation Commit-
tee)’s result reports (n97) of new products from August 2007 to November 2010,
which is open to the public. RESULTS: Among total 97 cases, the number of reim-
bursement decision was 58 (59.8%) at HIRA. The majority of reason for reimburse-
ment decision was lower treatment cost (67.2%). DREC accepted only 12 cases’ ICER
value for reimbursement decision, 85 decisions were made without PE result data.
Although clinical usefulness was improved in 33 cases, non-reimbursement deci-
sion was made in 6 cases because cost-effectiveness or PE data was uncertain.
Among 39 cases of non-reimbursement decisions, 10 cases accepted WAP
(Weighted Average Price) that HIRA suggested. Success rate of price negotiation at
NHIC was 68.0%, and took 3.7 months including administrative process from DREC
decision to MOHW (Ministry of Health and Welfare)’s final announcement. Average
duration for final reimbursement decision was 16.9 months. Approximately 7 more
months were necessary for applicant with PE data rather than without PE data (22.0
months vs. 15.0 months). CONCLUSIONS: The aim for introducing HTA is to list
drugs which prove clinical usefulness and cost effectiveness but this analysis
shows that it is difficult to expedite patient access to medicine through a HTA
environment in Korea. Alternatives beyond PE evidence are needed for timely pa-
tients’ access to innovative drugs.
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